Request Deal Involvement

F-Prime Capital, Forbion, and Norwest led a $157m Series B round in Engrail Therapeutics.

Identify your role

Select the side you represented in this transaction, and provide your current job title.

Service Providers

Latham & Watkins

legal advisors

Latham & Watkins

or

Principals

ENGRAIL THERAPEUTICS

target

ENGRAIL THERAPEUTICS

F-PRIME CAPITAL

bidder

F-PRIME CAPITAL

FORBION CAPITAL PARTNERS

bidder

FORBION CAPITAL PARTNERS

NORWEST VENTURE PARTNERS

bidder

NORWEST VENTURE PARTNERS

RIVERVEST VENTURE PARTNERS

bidder

RIVERVEST VENTURE PARTNERS

RED TREE VENTURE CAPITAL

bidder

RED TREE VENTURE CAPITAL

ABRDN INC

bidder

ABRDN INC

YSIOS CAPITAL

bidder

YSIOS CAPITAL

LONGWOOD FUND

bidder

LONGWOOD FUND

EIGHT ROADS VENTURES

bidder

EIGHT ROADS VENTURES

PIVOTAL LIFE SCIENCES

bidder

PIVOTAL LIFE SCIENCES

Principals or Service Provider not listed?Add missing Service Provider or Principal

Enter your Job Title on this deal

This title will appear on your profile next to this deal involvement.


To help us verify your involvement, please include links to any relevant publications that mention you or your company's role in this deal:

All rights reserved. Copyright © 2025 Datasite

MergerLinks - Request Credit - F-Prime Capital, Forbion, and Norwest led a $157m Series B round in Engrail Therapeutics.